Cumberland Pharmaceuticals (Nasdaq: CPIX) returns cash after $100M Apotex deal
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cumberland Pharmaceuticals Inc. authorized and declared a special cash dividend of $1.50 per share on its common stock, payable on or about July 31, 2026 to shareholders of record at the close of business on July 23, 2026. The board also approved a new open‑market share repurchase program authorizing up to $5 million of common stock over time, replacing the prior authorization.
These capital return actions follow a strategic transaction with Apotex Health Corp., under which Cumberland received $100 million in cash at closing for its line of FDA‑approved products and expects up to an additional $11 million tied to product inventory and transitional support services. After tax analysis and updated financial projections indicated greater net cash than first projected, the board assessed future cash needs and designated excess capital for the dividend and repurchase, while several directors plan new share purchase arrangements.
Cumberland retains its portfolio of product candidates and majority stake in Cumberland Emerging Technologies Inc. and will focus resources on late‑stage development of ifetroban for serious rare diseases, including Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis and high‑risk solid tumors, supported by multiple Phase II studies and U.S. FDA designations.
Positive
- $1.50 per share special cash dividend provides an immediate capital return to common shareholders, funded from excess cash generated by the Apotex strategic transaction.
- Cumberland received $100 million in cash at closing from Apotex and may receive up to an additional $11 million, providing substantial financial resources for both shareholder returns and development activities.
- The board authorized a new $5 million open‑market share repurchase program and highlighted ongoing insider share purchase plans, signaling continued alignment of capital allocation with equity ownership.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Special dividend per share: $1.50 per share
Dividend record date: July 23, 2026
Dividend payment date: July 31, 2026
+3 more
6 metrics
Special dividend per share
$1.50 per share
Cash dividend on common stock payable on or about July 31, 2026 to shareholders of record July 23, 2026.
Dividend record date
July 23, 2026
Shareholders of record at the close of business on this date are entitled to the $1.50 per share special dividend.
Dividend payment date
July 31, 2026
Date on or about which the special cash dividend is scheduled to be paid.
Apotex transaction upfront cash
$100 million
Cash received at closing from Apotex Health Corp. for Cumberland’s line of FDA-approved products.
Potential additional Apotex payments
up to $11 million
Additional amounts expected related to product inventory and transitional support services in the Apotex transaction.
New share repurchase authorization
up to $5 million
Open-market share repurchase program in Cumberland common stock authorized by the board.
Key Terms
special cash dividend, open-market share repurchase program, Orphan Drug, Rare Pediatric Disease, +2 more
6 terms
special cash dividend financial
"authorized and declared a special cash dividend of $1.50 per share of common stock"
A special cash dividend is a one-time, extra cash payment a company gives to its shareholders in addition to its regular dividends, like a bonus check sent out when a business has more cash than usual. It matters to investors because it delivers immediate cash value, can signal that the company has strong short-term cash or limited opportunities to reinvest, and typically reduces the company’s cash reserves and may affect the stock price and tax treatment for recipients.
Orphan Drug medical
"The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
Rare Pediatric Disease medical
"The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations"
A rare pediatric disease is a serious medical condition that primarily affects children and occurs so infrequently that only a small number of patients exist. Investors care because treatments for such conditions often get special regulatory incentives—think of government fast lanes and rewards for developers—making smaller markets potentially profitable due to pricing power, shorter development timelines, and reduced competition, much like a niche product that receives government-backed advantages.
Fast Track medical
"The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations"
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
Idiopathic Pulmonary Fibrosis medical
"A Phase II study evaluating ifetroban in patients with Idiopathic Pulmonary Fibrosis is actively enrolling"
Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.
FAQ
What special dividend did Cumberland Pharmaceuticals (CPIX) declare?
Cumberland declared a $1.50 per share special cash dividend on its common stock, payable on or about July 31, 2026 to shareholders of record at the close of business on July 23, 2026.
Why is Cumberland Pharmaceuticals (CPIX) paying a special dividend and launching a buyback?
Tax analysis and refined projections after the Apotex deal indicated greater net cash than expected. The board assessed future cash needs and chose a $1.50 per share special dividend plus a $5 million buyback for excess capital.
What are the key terms of Cumberland Pharmaceuticals’ (CPIX) transaction with Apotex?
Cumberland completed a strategic transaction with Apotex Health Corp., receiving $100 million in cash at closing for its FDA‑approved products and expecting up to $11 million in additional payments for inventory and transitional support services.
What is Cumberland Pharmaceuticals’ (CPIX) strategic focus after the Apotex transaction?
Cumberland will focus resources on developing ifetroban, advancing Phase II programs in Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis and cancer metastasis, while retaining its majority stake in Cumberland Emerging Technologies Inc.
What regulatory designations has ifetroban received in Duchenne muscular dystrophy cardiomyopathy?
The ifetroban program in Duchenne muscular dystrophy cardiomyopathy has received U.S. FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations, and Cumberland has reported breakthrough Phase II study results in this indication.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
July 13, 2026 (July 13, 2026 )
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices)
(615 ) 255-0068
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On July 13, 2026, the Board of Directors of Cumberland Pharmaceuticals Inc., (the “Cumberland” or “Company”) authorized and declared a special cash dividend of $1.50 per share of common stock payable in cash to the Company’s shareholders of record as of July 23, 2026. The dividend will be payable on or about July 31, 2026.
Cumberland previously announced the closing of a Strategic Transaction with Apotex Health Corp. (“Apotex”), an affiliate of Apotex, Inc., resulting in the integration of the U.S.-branded businesses. Cumberland received $100 million in cash at closing for its line of FDA-approved products. In addition, Cumberland expects to receive up to $11 million in additional payments associated with product inventory and transitional support services.
Following the closing of the transaction with Apotex, an analysis by the Company’s tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland’s Board of Directors met to assess the Company’s future cash needs and evaluate possible alternatives for the excess capital.
In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5 million in Cumberland shares of common stock over time. This replaces the previous share repurchase program established in January 2019 that allowed $10 million of share repurchases, of which $2.1 million remained available. The timing and actual number of shares repurchased pursuant the Company’s repurchase program will be determined by management depending on a variety of factors, including stock price, trading volume, market conditions, and other general business considerations. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company.
On July 13, 2026, the Company issued a press release announcing the special cash dividend. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 in this Current Report on Form 8-K by reference.
A copy of the release is furnished as Exhibit 99.1.
| Exhibit No. | Description | |||||||
99.1 | Press release dated July 13, 2026 | |||||||
FORWARD-LOOKING STATEMENTS
This filing contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland’s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland’s results of operations. These factors include market conditions, competition, the risks inherent in clinical development, regulatory review, and the commercialization of ifetroban and other pipeline or CET-supported assets, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company’s most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cumberland Pharmaceuticals Inc. | ||||||||||||||||||||
| Dated: July 13, 2026 | By: | /s/ John Hamm | ||||||||||||||||||
| John Hamm | ||||||||||||||||||||
| Chief Financial Officer | ||||||||||||||||||||
CUMBERLAND PHARMACEUTICALS
ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
Record Date is July 23, 2026 & Payment Date is July 31,2026
Corporate and Insider Share Purchase Initiatives to Continue
NASHVILLE, Tenn. (July 13, 2026) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company’s common stock. The dividend will be payable on or about July 31, 2026, to the shareholders of record at the close of business on July 23, 2026.
Cumberland previously announced the closing of a Strategic Transaction with Apotex Health Corp. (“Apotex”), resulting in the integration of the U.S.-branded businesses. Cumberland received $100 million in cash at closing for its line of FDA-approved products. In addition, Cumberland expects to receive up to $11 million in additional payments associated with product inventory and transitional support services.
Following the closing of the transaction with Apotex, an analysis by the Company’s tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland’s Board of Directors met to assess the Company’s future cash needs and evaluate possible alternatives for the excess capital.
In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5 million in Cumberland shares of common stock over time. The timing and actual number of shares repurchased pursuant the Company’s repurchase program will be determined by management depending on a variety of factors, including stock price, trading volume, market conditions, and other general business considerations. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company.
“In keeping with our ongoing commitment to deliver value to our shareholders, we are issuing a special dividend following the Strategic Transaction, which treats all shareholders equally,” said A.J. Kazimi, Cumberland’s CEO. “After the payout of $1.50 per share, we believe the Company will still have significant liquidity and financial flexibility to fund our long-term product development efforts, with additional reserves available to address any new opportunities”.
Cumberland has retained its robust portfolio of innovative product candidates and its majority ownership position in Cumberland Emerging Technologies Inc. Moving forward, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases:
•Duchenne Muscular Dystrophy Cardiomyopathy:
Cumberland announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with this rare, fatal genetic neuromuscular disease. Interactions with the FDA have been underway regarding study results and requirements for approval. The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations.
•Systemic Sclerosis:
Cumberland has conducted a Phase II clinical study evaluating the safety of ifetroban in patients with this debilitating autoimmune disorder. Evaluation of the study data is underway with top-line results anticipated as the next milestone.
•Idiopathic Pulmonary Fibrosis:
A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S. Favorable interim safety findings have been announced, and the next milestone is the announcement of the efficacy results.
•Cancer Metastasis:
Cumberland, in collaboration with Vanderbilt Health, recently announced the results of a Pilot Study of ifetroban in patients with high-risk solid tumors. The findings suggest the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo. The Phase 2 clinical trial also found ifetroban to be safe and well tolerated in the oncology patients, supporting further development of the drug to prevent cancer metastasis.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.
Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.
For more information, please visit www.cumberlandpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland’s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland’s results of operations. These factors include market conditions, competition, the risks inherent in clinical development, regulatory review, and the commercialization of ifetroban and other pipeline or CET-supported assets, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company’s most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
SOURCE: Cumberland Pharmaceuticals Inc.
Investor Contact: Shayla Simpson | Media Contact: Emily Kent | ||||
| Cumberland Pharmaceuticals Inc. | Dalton Agency | ||||
| (615) 255-0068 | (540) 621-5448 | ||||
###